Sulfonylureas in the news

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

Findings from a Scottish national cohort study show that the use of sulfonylureas as second-line glucose-lowering therapy is not associated with elevated cardiovascular risk or all-cause mortality.

People aged 60 years or older receiving thiazolidinedione monotherapy for type 2 diabetes may have a lower risk for dementia than those taking metformin monotherapy, an observational study suggests.

A number of factors are associated with severe hypoglycemia risk in people with type 2 diabetes treated with insulin or sulfonylureas, suggests research reported at the 58th EASD Annual Meeting in Stockholm, Sweden.

People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.

Initiating metformin following hospitalization for heart failure may reduce the risk for death or further HHF in older people with comorbid diabetes, but only if they have a preserved ejection fraction, study findings indicate.

Fewer than half of older adults receiving a sulfonylurea and/or insulin have their treatment deintensified after an emergency department visit or hospitalization for hypoglycemia, despite guidelines recommending this practice, US research shows.

The addition of liraglutide rather than extra oral antidiabetic drugs may offer more sustained glycemic control for people with type 2 diabetes who have inadequate control with metformin, suggest findings of the international LIRA-PRIME study.

Randomized trial findings presented at the virtual 57th EASD Annual Meeting suggest that treatment with a high dose of the SGLT2 inhibitor dapagliflozin may improve renal cortical oxygenation in people with type 1 diabetes and albuminuria.

Use of SGLT2 inhibitors rather than sulfonylureas as an addition to metformin therapy may be associated with a reduced mortality risk for people with type 2 diabetes, suggest real-world study findings.

Early achievement of a glycated hemoglobin (HbA1c) level below 7% is a key factor in maintaining long-term glucose control in people with type 2 diabetes initiating second-line glucose-lowering therapy, DISCOVER study data show.

Findings from the GRADE study, a head-to-head comparison of four commonly used diabetes drugs given together with metformin, suggest that liraglutide and insulin may result in better glycemic control than glimepiride and sitagliptin among people with type 2 diabetes.

Older people with type 2 diabetes are more likely to receive inappropriately intensive glucose-lowering treatment if they live in high- versus middle income countries, show data from the global DISCOVER study.

Combining metformin with a sulfonylurea produces poorer non-glycemic outcomes than combining it with other second-line agents, show results from the global DISCOVER program.

Older individuals with type 2 diabetes and low glycated hemoglobin receiving treatment with a sulfonylurea or insulin have an increased risk for severe hypoglycemia, but there is no clear indication of an increased mortality risk, suggest UK study results.

Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.

Adding linagliptin to glimepiride treatment reduces some measures of glycemic variability and improves glycemic control in patients with HNF1A-MODY, indicate findings from the GLIMLINA trial.

An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.

The reduced prostate cancer risk seen in men with diabetes may be partly explained by detection bias due to a lower biopsy rate following an elevated prostate-specific antigen test result, population-based study data show.

Research published in JAMA supports a beneficial cardiovascular safety profile for metformin relative to sulfonylureas in people with mild or moderate kidney dysfunction.